PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
15701869-0	2005	Biodistribution of yttrium-90-labeled anti-CD45 antibody in a nonhuman primate model.	Yttrium-90	19-29	protein tyrosine phosphatase receptor type C	Homo sapiens	43-47	
16939927-0	2006	[Labeling of CDTPA-dianhydride-coupled CD45 monoclonal antibody with yttrium-90].	Yttrium-90	69-79	protein tyrosine phosphatase receptor type C	Homo sapiens	39-43	
15701869-2	2005	We evaluated the organ localization of yttrium-90-labeled anti-CD45 ((90)Y-anti-CD45) antibody in macaques, a model that had previously predicted iodine-131-labeled anti-CD45 ((131)I-anti-CD45) antibody biodistribution in humans.	Yttrium-90	39-49	protein tyrosine phosphatase receptor type C	Homo sapiens	63-67	
15701869-2	2005	We evaluated the organ localization of yttrium-90-labeled anti-CD45 ((90)Y-anti-CD45) antibody in macaques, a model that had previously predicted iodine-131-labeled anti-CD45 ((131)I-anti-CD45) antibody biodistribution in humans.	Yttrium-90	39-49	protein tyrosine phosphatase receptor type C	Homo sapiens	80-84	
15701869-2	2005	We evaluated the organ localization of yttrium-90-labeled anti-CD45 ((90)Y-anti-CD45) antibody in macaques, a model that had previously predicted iodine-131-labeled anti-CD45 ((131)I-anti-CD45) antibody biodistribution in humans.	Yttrium-90	39-49	protein tyrosine phosphatase receptor type C	Homo sapiens	80-84	
15701869-2	2005	We evaluated the organ localization of yttrium-90-labeled anti-CD45 ((90)Y-anti-CD45) antibody in macaques, a model that had previously predicted iodine-131-labeled anti-CD45 ((131)I-anti-CD45) antibody biodistribution in humans.	Yttrium-90	39-49	protein tyrosine phosphatase receptor type C	Homo sapiens	80-84	
15701869-9	2005	Yttrium-90-labeled anti-CD45 antibody delivered 2.5- and 3.7-fold more radiation to marrow than to liver and lungs, respectively.	Yttrium-90	0-10	protein tyrosine phosphatase receptor type C	Homo sapiens	24-28	
32980545-3	2021	We performed sequential phase I trials of escalating doses of yttrium-90 (90Y)-labeled anti-CD45 antibody with or without BEAM chemotherapy followed by AHCT in adults with relapsed/refractory or high-risk B-cell non-Hodgkin lymphoma (NHL), T-NHL, or Hodgkin lymphoma (HL).	Yttrium-90	62-72	protein tyrosine phosphatase receptor type C	Homo sapiens	92-96